<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Neuro Farmacologia &#187; SSRIs</title>
	<atom:link href="http://www.neurofarmacologia.net/tag/ssris/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.neurofarmacologia.net</link>
	<description></description>
	<lastBuildDate>Tue, 27 Jul 2010 08:11:45 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>La sindrome serotoninergica, un approccio pratico</title>
		<link>http://www.neurofarmacologia.net/2010/07/26/la-sindrome-serotoninergica-un-approccio-pratico-alla-diagnosi-e-al-trattamento/</link>
		<comments>http://www.neurofarmacologia.net/2010/07/26/la-sindrome-serotoninergica-un-approccio-pratico-alla-diagnosi-e-al-trattamento/#comments</comments>
		<pubDate>Mon, 26 Jul 2010 11:42:17 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[farmacologia clinica]]></category>
		<category><![CDATA[informazione medica]]></category>
		<category><![CDATA[la mente ed il suo cervello]]></category>
		<category><![CDATA[5HT]]></category>
		<category><![CDATA[citalopram]]></category>
		<category><![CDATA[disturbi d'ansia]]></category>
		<category><![CDATA[effetti collaterali]]></category>
		<category><![CDATA[effetti indesiderati]]></category>
		<category><![CDATA[escitalopram]]></category>
		<category><![CDATA[eventi avversi]]></category>
		<category><![CDATA[fluoxetina]]></category>
		<category><![CDATA[fluvoxamina]]></category>
		<category><![CDATA[Imao]]></category>
		<category><![CDATA[inibitori monoamino ossidasi]]></category>
		<category><![CDATA[iperico]]></category>
		<category><![CDATA[paroxetina]]></category>
		<category><![CDATA[serotonina]]></category>
		<category><![CDATA[sertralina]]></category>
		<category><![CDATA[sindrome serotoninergica]]></category>
		<category><![CDATA[SSRIs]]></category>
		<category><![CDATA[tossicità]]></category>
		<category><![CDATA[triptofano]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=1006</guid>
		<description><![CDATA[Con l’introduzione di un numero sempre maggior di farmaci che agiscono attraverso il sistema serotoninergico cerebrale la tossicità da serotonina è diventato un evento avverso di crescente importanza. Molti farmaci sono stati chiamati in causa nella fisiopatologia della sindrome serotoninergica tra cui gli inibitori della ricaptazione della serotonina (SSRIs) . Per evitare fraintendimenti è fondamentale [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2010/07/26/la-sindrome-serotoninergica-un-approccio-pratico-alla-diagnosi-e-al-trattamento/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Antidepressivi ed aumento di peso</title>
		<link>http://www.neurofarmacologia.net/2010/02/25/antidepressivi-ed-aumento-di-peso/</link>
		<comments>http://www.neurofarmacologia.net/2010/02/25/antidepressivi-ed-aumento-di-peso/#comments</comments>
		<pubDate>Thu, 25 Feb 2010 09:02:23 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[disturbi dell'umore]]></category>
		<category><![CDATA[disturbi della condotta alimentare]]></category>
		<category><![CDATA[farmacologia clinica]]></category>
		<category><![CDATA[informazione medica]]></category>
		<category><![CDATA[antidepressivi]]></category>
		<category><![CDATA[aumento di peso]]></category>
		<category><![CDATA[benessere]]></category>
		<category><![CDATA[bupropione]]></category>
		<category><![CDATA[calorie]]></category>
		<category><![CDATA[citalopram]]></category>
		<category><![CDATA[effetti collaterali]]></category>
		<category><![CDATA[efficacia]]></category>
		<category><![CDATA[escitalopram]]></category>
		<category><![CDATA[farmaci]]></category>
		<category><![CDATA[farmaci ingrassanti]]></category>
		<category><![CDATA[fluoxetina]]></category>
		<category><![CDATA[fluvoxamina]]></category>
		<category><![CDATA[grasso]]></category>
		<category><![CDATA[Imao]]></category>
		<category><![CDATA[Mirtazapina]]></category>
		<category><![CDATA[nefazodone]]></category>
		<category><![CDATA[paroxetina]]></category>
		<category><![CDATA[peso]]></category>
		<category><![CDATA[salute]]></category>
		<category><![CDATA[sertralina]]></category>
		<category><![CDATA[spettro d'azione]]></category>
		<category><![CDATA[SSRIs]]></category>
		<category><![CDATA[trazodone]]></category>
		<category><![CDATA[triciclici]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=902</guid>
		<description><![CDATA[Nell&#8217;ambito dei medicinali ad azione antidepressiva sono compresi  farmaci con meccanismi di azione estremamente differenti tra loro e per tale motivo può essere fuorviante descrivere le loro caratteristiche come se fossero una unica classe farmacologica. Per illustrare l&#8217;effetto dei farmaci antidepressivi sul peso corporeo è necessario quindi separare le diverse molecole (almeno in base al [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2010/02/25/antidepressivi-ed-aumento-di-peso/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Depressione Maggiore, i sintomi residui e le opzioni di trattamento</title>
		<link>http://www.neurofarmacologia.net/2010/02/18/depressione-maggiore-i-sintomi-residui-e-le-opzioni-di-trattamento/</link>
		<comments>http://www.neurofarmacologia.net/2010/02/18/depressione-maggiore-i-sintomi-residui-e-le-opzioni-di-trattamento/#comments</comments>
		<pubDate>Thu, 18 Feb 2010 08:49:43 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[disturbi dell'umore]]></category>
		<category><![CDATA[farmacologia clinica]]></category>
		<category><![CDATA[i disturbi del comportamento]]></category>
		<category><![CDATA[informazione medica]]></category>
		<category><![CDATA[antidepressivi]]></category>
		<category><![CDATA[antipsicotici atipici]]></category>
		<category><![CDATA[aripiprazolo]]></category>
		<category><![CDATA[combinazione]]></category>
		<category><![CDATA[depressione]]></category>
		<category><![CDATA[dopamino agonisti]]></category>
		<category><![CDATA[efficacia]]></category>
		<category><![CDATA[litio]]></category>
		<category><![CDATA[maneggevolezza]]></category>
		<category><![CDATA[olanzapina]]></category>
		<category><![CDATA[opzioni]]></category>
		<category><![CDATA[pindololo]]></category>
		<category><![CDATA[pontenziamento]]></category>
		<category><![CDATA[psicostimolanti]]></category>
		<category><![CDATA[psicoterapia]]></category>
		<category><![CDATA[sicurezza]]></category>
		<category><![CDATA[sintomi residui]]></category>
		<category><![CDATA[SSRIs]]></category>
		<category><![CDATA[terapie associazione]]></category>
		<category><![CDATA[tollerabvilità]]></category>
		<category><![CDATA[trattamento]]></category>
		<category><![CDATA[triciclici]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=886</guid>
		<description><![CDATA[Dal 29 al 46% dei pazienti affetti da depressione continuano a presentare sintomi residui di malattia nonostante assumano correttamente  un adeguato  trattamento. Pertanto, anche tra coloro che rispondono alla terapia antidepressiva, vi sono persone che continuano ad avere sintomi anche se di ridotta intensità o in numero minore. Tali sintomi, oltre a condizionare negativamente la [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2010/02/18/depressione-maggiore-i-sintomi-residui-e-le-opzioni-di-trattamento/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>trattamenti antidepressivi e depressione bipolare, rapporto tra rischio e beneficio</title>
		<link>http://www.neurofarmacologia.net/2010/01/19/trattamenti-antidepressivi-e-depressione-bipolare-rapporto-tra-rischio-e-beneficio-2/</link>
		<comments>http://www.neurofarmacologia.net/2010/01/19/trattamenti-antidepressivi-e-depressione-bipolare-rapporto-tra-rischio-e-beneficio-2/#comments</comments>
		<pubDate>Tue, 19 Jan 2010 10:37:39 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[disturbi dell'umore]]></category>
		<category><![CDATA[farmacologia clinica]]></category>
		<category><![CDATA[i disturbi del comportamento]]></category>
		<category><![CDATA[informazione medica]]></category>
		<category><![CDATA[antidepressivi]]></category>
		<category><![CDATA[antidepressivi triciclici]]></category>
		<category><![CDATA[depressione bipolare]]></category>
		<category><![CDATA[eccitamento maniacale]]></category>
		<category><![CDATA[fase maniacale]]></category>
		<category><![CDATA[inibitori selettivi della ricaptazione della serotonina]]></category>
		<category><![CDATA[ipomania]]></category>
		<category><![CDATA[mania]]></category>
		<category><![CDATA[paroxetina]]></category>
		<category><![CDATA[rischio di viraggio]]></category>
		<category><![CDATA[SSRIs]]></category>
		<category><![CDATA[trattamento farmacologico]]></category>
		<category><![CDATA[trimipramina]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=669</guid>
		<description><![CDATA[Durante i trattamenti antidepressivi il rischio di indurre o slatentizzare un disturbo bipolare è una delle principali preoccupazioni dello psichiatra. Dal punto di vista dell&#8217;osservazione clinica trasversale, cioè al momento della visita, le depressioni unipolari (cioè i disturbi caratterizzati eslusivamente da fasi depressive) e le depressioni bipolari (cioè i disturbi caratterizzati da fasi depressive alternate [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2010/01/19/trattamenti-antidepressivi-e-depressione-bipolare-rapporto-tra-rischio-e-beneficio-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>SSRIs e disfunzioni sessuali, strategie terapeutiche</title>
		<link>http://www.neurofarmacologia.net/2009/10/30/ssris-e-disfunzioni-sessuali-strategie-terapeutiche/</link>
		<comments>http://www.neurofarmacologia.net/2009/10/30/ssris-e-disfunzioni-sessuali-strategie-terapeutiche/#comments</comments>
		<pubDate>Fri, 30 Oct 2009 10:12:15 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[disturbi dell'umore]]></category>
		<category><![CDATA[farmacologia clinica]]></category>
		<category><![CDATA[i disturbi del comportamento]]></category>
		<category><![CDATA[informazione medica]]></category>
		<category><![CDATA[amantadina]]></category>
		<category><![CDATA[antidepressivi]]></category>
		<category><![CDATA[antidepressivi triciclici]]></category>
		<category><![CDATA[attività sessuale]]></category>
		<category><![CDATA[bupropione]]></category>
		<category><![CDATA[buspirone]]></category>
		<category><![CDATA[citalopram]]></category>
		<category><![CDATA[depressione]]></category>
		<category><![CDATA[desiderio]]></category>
		<category><![CDATA[disfunzioni sessuali]]></category>
		<category><![CDATA[duloxetina]]></category>
		<category><![CDATA[effetti collaterali]]></category>
		<category><![CDATA[effetti indesiderati]]></category>
		<category><![CDATA[eiaculazione precoce]]></category>
		<category><![CDATA[escitalopram]]></category>
		<category><![CDATA[fluoxetina]]></category>
		<category><![CDATA[fluvoxamina]]></category>
		<category><![CDATA[gestione effetti collaterali]]></category>
		<category><![CDATA[inibitori della ricaptazione della serotonina]]></category>
		<category><![CDATA[inibizione]]></category>
		<category><![CDATA[latenza]]></category>
		<category><![CDATA[libido]]></category>
		<category><![CDATA[meccanismo d'azione]]></category>
		<category><![CDATA[Mirtazapina]]></category>
		<category><![CDATA[NARI]]></category>
		<category><![CDATA[nefazodone]]></category>
		<category><![CDATA[noradrenalina]]></category>
		<category><![CDATA[orgasmo]]></category>
		<category><![CDATA[paroxetina]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[raggiungimento]]></category>
		<category><![CDATA[riduzione funzione sessuale]]></category>
		<category><![CDATA[serotonina]]></category>
		<category><![CDATA[sertralina]]></category>
		<category><![CDATA[sfera sessuale]]></category>
		<category><![CDATA[sildenafil]]></category>
		<category><![CDATA[SNRIs]]></category>
		<category><![CDATA[SSRIs]]></category>
		<category><![CDATA[strategie terapeutiche]]></category>
		<category><![CDATA[tadalafil]]></category>
		<category><![CDATA[TCI]]></category>
		<category><![CDATA[valutazione]]></category>
		<category><![CDATA[venlafaxina]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=716</guid>
		<description><![CDATA[Gli inibitori della ricaptazione della serotonina (SSRIS) sono uno dei trattamenti antidepressivi più frequentemente prescritti. Abbiamo visto precedentemente (www.neurofarmacologia.net/25/10/2009/ssris-e-disfunzioni-sessuali-la-valutazione-clinica/#more-713) come, nonostante il loro discreto profilo di tollerabilità, questi farmaci possano essere coinvolti nella fisiopatologia di alcune disfunzioni della sfera sessuale. Quando si verificano questo tipo di effetti indesiderati si dovrebbe in primo luogo tenere presente [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2009/10/30/ssris-e-disfunzioni-sessuali-strategie-terapeutiche/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>SSRIs e disfunzioni sessuali, la valutazione clinica</title>
		<link>http://www.neurofarmacologia.net/2009/10/25/ssris-e-disfunzioni-sessuali-la-valutazione-clinica/</link>
		<comments>http://www.neurofarmacologia.net/2009/10/25/ssris-e-disfunzioni-sessuali-la-valutazione-clinica/#comments</comments>
		<pubDate>Sun, 25 Oct 2009 15:14:56 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[disturbi dell'umore]]></category>
		<category><![CDATA[farmacologia clinica]]></category>
		<category><![CDATA[i disturbi del comportamento]]></category>
		<category><![CDATA[informazione medica]]></category>
		<category><![CDATA[antidepressivi]]></category>
		<category><![CDATA[antidepressivi triciclici]]></category>
		<category><![CDATA[attività sessuale]]></category>
		<category><![CDATA[bupropione]]></category>
		<category><![CDATA[citalopram]]></category>
		<category><![CDATA[depressione]]></category>
		<category><![CDATA[desiderio]]></category>
		<category><![CDATA[disfunzioni sessuali]]></category>
		<category><![CDATA[duloxetina]]></category>
		<category><![CDATA[effetti collaterali]]></category>
		<category><![CDATA[effetti indesiderati]]></category>
		<category><![CDATA[eiaculazione precoce]]></category>
		<category><![CDATA[escitalopram]]></category>
		<category><![CDATA[fluoxetina]]></category>
		<category><![CDATA[fluvoxamina]]></category>
		<category><![CDATA[inibitori della ricaptazione della serotonina]]></category>
		<category><![CDATA[inibizione]]></category>
		<category><![CDATA[latenza]]></category>
		<category><![CDATA[libido]]></category>
		<category><![CDATA[meccanismo d'azione]]></category>
		<category><![CDATA[Mirtazapina]]></category>
		<category><![CDATA[NARI]]></category>
		<category><![CDATA[nefazodone]]></category>
		<category><![CDATA[noradrenalina]]></category>
		<category><![CDATA[orgasmo]]></category>
		<category><![CDATA[paroxetina]]></category>
		<category><![CDATA[raggiungimento]]></category>
		<category><![CDATA[riduzione funzione sessuale]]></category>
		<category><![CDATA[serotonina]]></category>
		<category><![CDATA[sertralina]]></category>
		<category><![CDATA[sfera sessuale]]></category>
		<category><![CDATA[sildenafil]]></category>
		<category><![CDATA[SNRIs]]></category>
		<category><![CDATA[SSRIs]]></category>
		<category><![CDATA[tadalafil]]></category>
		<category><![CDATA[TCI]]></category>
		<category><![CDATA[valutazione]]></category>
		<category><![CDATA[venlafaxina]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=713</guid>
		<description><![CDATA[Gli inibitori della ricaptazione della serotonina (SSRIS) sono uno dei trattamenti antidepressivi più frequentemente prescritti nel nostro paese ed alcuni tra i farmaci più prescritti in tutto il mondo. La riduzione della funzione sessuale è uno dei sintomi depressivi più comuni e che migliora in breve tempo con un trattamento antidepressivo efficace. Le disfunzioni sessuali [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2009/10/25/ssris-e-disfunzioni-sessuali-la-valutazione-clinica/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>trattamenti antidepressivi e depressione bipolare, rapporto tra rischio e beneficio</title>
		<link>http://www.neurofarmacologia.net/2009/09/24/trattamenti-antidepressivi-e-depressione-bipolare-rapporto-tra-rischio-e-beneficio/</link>
		<comments>http://www.neurofarmacologia.net/2009/09/24/trattamenti-antidepressivi-e-depressione-bipolare-rapporto-tra-rischio-e-beneficio/#comments</comments>
		<pubDate>Thu, 24 Sep 2009 08:20:40 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[farmacologia clinica]]></category>
		<category><![CDATA[informazione medica]]></category>
		<category><![CDATA[antidepressivi triciclici]]></category>
		<category><![CDATA[Dapagut]]></category>
		<category><![CDATA[Daparox]]></category>
		<category><![CDATA[depressione bipolare]]></category>
		<category><![CDATA[depressione unipolare]]></category>
		<category><![CDATA[inibitori selettivi della ricaptazione della serotonina]]></category>
		<category><![CDATA[paroxetina]]></category>
		<category><![CDATA[paxil]]></category>
		<category><![CDATA[Sereupin]]></category>
		<category><![CDATA[Seroxat]]></category>
		<category><![CDATA[SSRIs]]></category>
		<category><![CDATA[Surmontil]]></category>
		<category><![CDATA[terapie antidepressive]]></category>
		<category><![CDATA[trimipramina]]></category>
		<category><![CDATA[viraggio maniacale]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=648</guid>
		<description><![CDATA[Durante i trattamenti antidepressivi il rischio di indurre o slatentizzare un disturbo bipolare è una delle principali preoccupazioni dello psichiatra. Dal punto di vista dell&#8217;osservazione clinica trasversale (cioè la valutazione dei sintomi presentati al momento della visita e non il decorso precedente e la storia familiare) le depressioni unipolari (cioè i disturbi caratterizzati eslusivamente da [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2009/09/24/trattamenti-antidepressivi-e-depressione-bipolare-rapporto-tra-rischio-e-beneficio/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Gli antidepressivi sono tutti uguali?</title>
		<link>http://www.neurofarmacologia.net/2009/06/02/gli-antidepressivi-sono-tutti-uguali/</link>
		<comments>http://www.neurofarmacologia.net/2009/06/02/gli-antidepressivi-sono-tutti-uguali/#comments</comments>
		<pubDate>Tue, 02 Jun 2009 10:22:06 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[disturbi dell'umore]]></category>
		<category><![CDATA[farmacologia clinica]]></category>
		<category><![CDATA[informazione medica]]></category>
		<category><![CDATA[antidepressivi]]></category>
		<category><![CDATA[Cipralex]]></category>
		<category><![CDATA[citalopram]]></category>
		<category><![CDATA[Cymbalta]]></category>
		<category><![CDATA[Dapagutt]]></category>
		<category><![CDATA[Daparox]]></category>
		<category><![CDATA[Davedax]]></category>
		<category><![CDATA[dopamina]]></category>
		<category><![CDATA[duloxetina]]></category>
		<category><![CDATA[Edronax]]></category>
		<category><![CDATA[Efexor]]></category>
		<category><![CDATA[Entact]]></category>
		<category><![CDATA[escitalopram]]></category>
		<category><![CDATA[Eutimil]]></category>
		<category><![CDATA[Faxine]]></category>
		<category><![CDATA[Fluoxeren]]></category>
		<category><![CDATA[fluoxetina]]></category>
		<category><![CDATA[fluvoxamina]]></category>
		<category><![CDATA[inibitori della ricaptazione della serotonina]]></category>
		<category><![CDATA[meccanismo d'azione]]></category>
		<category><![CDATA[neurone]]></category>
		<category><![CDATA[paroxetina]]></category>
		<category><![CDATA[Prozac]]></category>
		<category><![CDATA[reboxetina]]></category>
		<category><![CDATA[recettore]]></category>
		<category><![CDATA[Remeron]]></category>
		<category><![CDATA[Sereupin]]></category>
		<category><![CDATA[Seroxat]]></category>
		<category><![CDATA[sertralina]]></category>
		<category><![CDATA[sinapsi]]></category>
		<category><![CDATA[sistema nervoso centrale]]></category>
		<category><![CDATA[SNRIs]]></category>
		<category><![CDATA[SSRIs]]></category>
		<category><![CDATA[Tatig]]></category>
		<category><![CDATA[venlafaxina]]></category>
		<category><![CDATA[Xeristar]]></category>
		<category><![CDATA[Zoloft]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=514</guid>
		<description><![CDATA[Dopo che su questo blog avevamo cercato di fare un po’ di chiarezza su quanto i farmaci che inibiscono selettivamente la ricaptazione di serotonina siano differenti tra loro http://www.neurofarmacologia.net/02/01/2009/gli-inibitori-della-ricaptazione-della-serotonina-sono-tutti-uguali/ ecco che sull’argomento si pronuncia l’autorevole rivista “Lancet”. In un recente articolo un gruppo di autori italiani ed internazionali hanno analizzato una mole impressionante di dati, [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2009/06/02/gli-antidepressivi-sono-tutti-uguali/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
		</item>
		<item>
		<title>selective serotonine reuptake inibitors and suicidal behavior</title>
		<link>http://www.neurofarmacologia.net/2009/04/26/selective-serotonine-reuptake-inibitors-and-suicidal-behavior/</link>
		<comments>http://www.neurofarmacologia.net/2009/04/26/selective-serotonine-reuptake-inibitors-and-suicidal-behavior/#comments</comments>
		<pubDate>Sun, 26 Apr 2009 15:28:49 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[English Text]]></category>
		<category><![CDATA[disturbi dell'umore]]></category>
		<category><![CDATA[farmacologia clinica]]></category>
		<category><![CDATA[antidepressants]]></category>
		<category><![CDATA[citalopram]]></category>
		<category><![CDATA[depression]]></category>
		<category><![CDATA[epidemiological studies]]></category>
		<category><![CDATA[escitalopram]]></category>
		<category><![CDATA[evidence based studies]]></category>
		<category><![CDATA[fluoxetine]]></category>
		<category><![CDATA[fluvoxamine]]></category>
		<category><![CDATA[good clinical practice]]></category>
		<category><![CDATA[paroxetine]]></category>
		<category><![CDATA[randomized controlled trials]]></category>
		<category><![CDATA[selective serotonine reuptake inibitors]]></category>
		<category><![CDATA[sertraline]]></category>
		<category><![CDATA[SSRIs]]></category>
		<category><![CDATA[suicidal behavior]]></category>
		<category><![CDATA[suicide]]></category>
		<category><![CDATA[suicide risk]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=418</guid>
		<description><![CDATA[In the last years a variety of anecdotal studies suggested that treatment with selective sertraline inibitors (SSRIs) (paroxetine, sertraline, citalopram, escitalopram, fluoxetine, fluvoxamine) may induce suicidal behaviours. Taking into account all methodological difficulties in studying suicidal behaviour in a population of depressed patients (by definition with higher suicide risk than general population), a revision of [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2009/04/26/selective-serotonine-reuptake-inibitors-and-suicidal-behavior/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sertraline treatment of Bulimia Nervosa</title>
		<link>http://www.neurofarmacologia.net/2009/04/08/sertraline-treatment-of-bulimia-nervosa/</link>
		<comments>http://www.neurofarmacologia.net/2009/04/08/sertraline-treatment-of-bulimia-nervosa/#comments</comments>
		<pubDate>Wed, 08 Apr 2009 12:36:54 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[English Text]]></category>
		<category><![CDATA[disturbi della condotta alimentare]]></category>
		<category><![CDATA[Binging Purging Type Anorexia]]></category>
		<category><![CDATA[body weight]]></category>
		<category><![CDATA[bulimia nervosa]]></category>
		<category><![CDATA[control trials]]></category>
		<category><![CDATA[drug treatment]]></category>
		<category><![CDATA[Eating Disorders]]></category>
		<category><![CDATA[fluoxetine]]></category>
		<category><![CDATA[obesity]]></category>
		<category><![CDATA[sertraline]]></category>
		<category><![CDATA[SSRIs]]></category>
		<category><![CDATA[weight gain]]></category>
		<category><![CDATA[weight loss]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=389</guid>
		<description><![CDATA[Control trials show that fluoxetine is effective in Eating Disorders, particularly in bulimia nervosa. Despite the relative paucity of evidence other selective serotonine reuptake inhibitors (SSRIs) than fluoxetine are commonly used to treat bulimia nervosa in clinical practice. Sertraline is one of the SSRIs being used in Eating Disorders with binging and purging behaviors. Available [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2009/04/08/sertraline-treatment-of-bulimia-nervosa/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
